Edition:
United Kingdom

Apollo Endosurgery Inc (APEN.OQ)

APEN.OQ on NASDAQ Stock Exchange Global Market

6.44USD
20 Feb 2018
Change (% chg)

$0.01 (+0.16%)
Prev Close
$6.43
Open
$6.37
Day's High
$6.49
Day's Low
$6.37
Volume
1,172
Avg. Vol
33,317
52-wk High
$14.09
52-wk Low
$3.60

Chart for

About

Apollo Endosurgery, Inc., formerly Lpath, Inc., is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company's device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80... (more)

Overall

Beta: 0.47
Market Cap(Mil.): $94.37
Shares Outstanding(Mil.): 17.25
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.19 16.60
EPS (TTM): -- -- --
ROI: -- 13.90 10.66
ROE: -- 16.72 14.30

BRIEF-Apollo Endosurgery Inc Files For Stock Shelf Of Upto $50 Million - SEC Filing ‍​

* APOLLO ENDOSURGERY INC FILES FOR STOCK SHELF OF UPTO $50 MILLION - SEC FILING ‍​ Source text (http://bit.ly/2AONduG) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

04 Dec 2017

BRIEF-Apollo Endosurgery Receives FDA Clearance For Overstitch Sx Endoscopic Suturing System

* APOLLO ENDOSURGERY RECEIVES FDA CLEARANCE FOR OVERSTITCH™ SX ENDOSCOPIC SUTURING SYSTEM

27 Nov 2017

BRIEF-David Pacitti joins Apollo Endosurgery board of directors

* David C. Pacitti joins Apollo Endosurgery board of directors

16 Nov 2017

BRIEF-Apollo Endosurgery reports qtrly loss per share $‍0.32​

* Apollo Endosurgery Inc - qtrly loss per share $‍0.32​ Source text for Eikon: Further company coverage:

26 Oct 2017

BRIEF-Apollo endosurgery announces CE mark approval for the Orbera365™ managed weight loss system,

* Apollo Endosurgery announces CE mark approval for the Orbera365™ managed weight loss system, expanding the indwell period from 6 months to 12 months with the gastric balloon category leader

30 Aug 2017

Earnings vs. Estimates